Clinical Trials Logo

Solid Tumors and Lymphomas clinical trials

View clinical trials related to Solid Tumors and Lymphomas.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT00457574 Withdrawn - Clinical trials for Solid Tumors and Lymphomas

Safety and Efficacy of GMX1777 in the Treatment of Refractory Solid Tumors or Lymphomas

Start date: March 2007
Phase: Phase 1
Study type: Interventional

GMX1777 is a water-soluble, intravenously-administered prodrug of GMX1778. GMX1777 is rapidly converted to GMX1778 in vivo. GMX1778 has potent anti-tumor activity against a variety of cell lines and models from different tumor origins.